Comparative Pharmacology
Head-to-head clinical analysis: HYCODAN versus PENNTUSS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYCODAN versus PENNTUSS.
HYCODAN vs PENNTUSS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a full mu-opioid receptor agonist; homatropine is an anticholinergic agent that reduces excessive respiratory tract secretions.
PENNTUSS contains hydrocodone, a semisynthetic opioid agonist with antitussive activity, and pseudoephedrine, a sympathomimetic amine. Hydrocodone acts primarily on mu-opioid receptors in the cough center of the medulla oblongata to increase cough threshold. Pseudoephedrine stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1 tablet (5 mg hydrocodone/1.5 mg homatropine) orally every 4 to 6 hours as needed for cough; maximum 6 tablets per 24 hours.
5 mL (equivalent to hydrocodone 5 mg and homatropine 1.5 mg) orally every 4 to 6 hours as needed for cough; maximum 30 mL (hydrocodone 30 mg) per day.
None Documented
None Documented
Terminal elimination half-life of hydrocodone is 3.8-5.7 hours (mean 4.5 h) in adults; clinical duration of analgesia is 4-6 hours. Half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life is approximately 2–4 hours in adults. In renal impairment, half-life may be prolonged due to reduced clearance.
Renal elimination of unchanged drug (hydrocodone: ~26%; homatropine: negligible) and glucuronide conjugates (hydrocodone: ~40% as hydromorphone and norhydrocodone). Biliary/fecal excretion accounts for ~20-30%.
Primarily renal as unchanged drug and metabolites. Approximately 60% of a dose is excreted renally within 24 hours (about 20% unchanged), with the remainder as glucuronide and oxidative metabolites. Minor biliary/fecal elimination (<10%).
Category C
Category C
Opioid Antitussive
Opioid Antitussive